News with Multimedia
-
Critères principal atteint dans une étude clinique comparative de phase 3 sur le candidat biosimilaire HLX11 du Perjeta® (pertuzumab)
09/30/2024 - 11:59 PM
-
Perjeta®（帕妥珠单抗）生物类似药HLX11临床III期对照研究达到主要研究终点
09/30/2024 - 11:59 PM
-
VicOne Achieves TISAX Assessment Level 3 Assuring Customers of Highest Level of Data Protection and Security Excellence in the Automotive Industry
09/30/2024 - 11:48 PM
-
FPT Software remporte le Job Creation Award aux ESGBusiness Awards 2024
09/30/2024 - 11:38 PM
-
FPT Software erhält den Job Creation Award im Rahmen der ESGBusiness Awards 2024
09/30/2024 - 11:38 PM
-
Sino-European Corporate ESG Best Practice Conference Recognizes China’s Taicang High-Tech Zone for Its Sino-German Collaboration, Driving ESG Development
09/30/2024 - 11:11 PM
-
Se cumple el criterio de valoración principal en el ensayo clínico comparativo de fase 3 del candidato a biosimilar de Perjeta® (pertuzumab) HLX11
09/30/2024 - 09:20 PM
-
Dopavision Presented Key Data From Its MyopiaX-1 Clinical Trial at the 19th International Myopia Conference
09/30/2024 - 09:00 PM
-
WNS and Uniqus Join Forces to Offer Sustainability and Technical Accounting & Reporting Consulting Services
09/30/2024 - 08:00 PM -
Guangdong Province Champions the Preservation and Promotion of Lingnan Culture
09/30/2024 - 07:49 PM
-
“Charming Beijing” Exhibition Highlights World Cultural Heritage for European Audiences
09/30/2024 - 07:17 PM
-
FPT Software Wins Job Creation Award at ESGBusiness Awards 2024
09/30/2024 - 06:17 PM
-
Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
09/30/2024 - 06:00 PM
-
A research paper on AI-driven drug discovery by SAKURA internet and COGNANO was accepted by NeurIPS 2024, a prestigious AI conference
09/30/2024 - 05:00 PM
-
COMPLEXION to Exhibit at GITEX Global 2024, the Largest IT Show in the Middle East
09/30/2024 - 04:00 PM